FDA Depositions Reveal Crawford’s Prominent Role In Plan B Switch Review
This article was originally published in The Tan Sheet
Executive Summary
The role of high-level FDA officials in the review of Barr Labs' Rx-to-OTC switch application for Plan B was required by the "high-profile" nature of the NDA, according to Center for Drug Evaluation & Research Director Steven Galson
You may also be interested in...
Crawford Pleads Guilty Of Failing To Disclose Stocks In Firms FDA Regulates
Former FDA Commissioner Lester Crawford on Oct. 17 pleaded guilty in federal court to charges related to owning stocks in companies regulated by the agency
CDER Officials Testify On Behind-The-Scenes Maneuvers In Plan B Rejection
The initial rejection of Barr's Rx-to-OTC switch application for Plan B may have been intended to lead eventually to a restricted approval, according to deposition testimony from FDA officials
Plan B Draws Criticism During Von Eschenbach Confirmation Hearing
FDA's recent request to meet with Barr Labs about the proposed OTC sale of Plan B has done little to quell criticisms from Senate Democrats concerning the agency's extensive delays in issuing a decision on the Rx-to-OTC switch application